TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AIM ImmunoTech ( (AIM) ) has shared an update.
On November 18, 2025, AIM ImmunoTech Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC, resulting in the sale of an unsecured Promissory Note with a principal amount of $3,301,250. The transaction, which closed on the same date, involved a purchase price of $2,500,000 after accounting for an issuance discount and transaction costs. The Note bears a 10% annual interest rate, with a maturity date set for 24 months from issuance. The agreement includes mandatory prepayment terms tied to future fundraising activities and outlines conditions for default, which could lead to increased interest rates.
The most recent analyst rating on (AIM) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
AIM ImmunoTech’s overall stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company’s financial instability, characterized by negative equity and cash flow issues, is the most significant factor. The technical analysis further supports a negative outlook with indicators pointing to an oversold and downtrending stock. Valuation concerns, including a negative P/E ratio, also contribute to the low score.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
Average Trading Volume: 100,576
Technical Sentiment Signal: Sell
Current Market Cap: $3.98M
See more insights into AIM stock on TipRanks’ Stock Analysis page.